NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
08 mars 2024 16h05 HE
|
NurExone Biologic Inc
NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel
NurExone’s Intellectual Property Portfolio Expands
20 févr. 2024 16h05 HE
|
NurExone Biologic Inc
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
NurExone Launches Licensing Efforts for ExoTherapy Platform
14 févr. 2024 16h20 HE
|
NurExone Biologic Inc
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
05 févr. 2024 09h00 HE
|
Yiviva
NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed...
Starton Therapeutics Announces STARTICLES Filing
17 janv. 2024 15h12 HE
|
Starton Therapeutics
STARTICLES, referring to proprietary and novel solid-state particulates suspended within a drug-in-adhesive patch for delivery of active pharmaceutical ingredients (API) developed by Starton...
AstriVax Awarded €3 Million Grant to Advance therapeutic Hepatitis B Vaccine
12 déc. 2023 01h00 HE
|
AstriVax
The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO).The grant will be used to accelerate the development of the company’s therapeutic vaccine targeting chronic...
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
30 nov. 2022 15h01 HE
|
POP Biotechnologies
BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2...
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
20 sept. 2022 21h31 HE
|
POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...
ProLynx appoints Richard King as Chief Executive Officer and Chris Ehrlich as Board Director
20 sept. 2022 06h00 HE
|
ProLynx LLC
SAN FRANCISCO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- ProLynx, Inc., a biotechnology company with a novel platform technology for half-life extension of therapeutics, enabling novel and potentially...